Anti-Ixekizumab Antibodies

s

s

s

Antibodies for bioanalysis and drug monitoring of ixekizumab and biosimilars

Develop highly selective and sensitive PK and ADA assays for the humanized antibody drug ixekizumab (Taltz®) using our range of ready-made anti-idiotypic antibodies.

• Inhibitory and non-inhibitory antibodies specific to ixekizumab
• Fully human surrogate positive control or calibrator
• Sequence defined, well characterized reagents with secure supply
• Recombinant production, stringent quality control for batch-to-batch consistency
• Non-animal-derived antibodies, reducing the use of animals in science

Table 1. Antibodies Specific to Ixekizumab.

* Affinity measured in the monovalent Fab format.
¹ Fab-F-Spy2-H = Monovalent Fab antibody with (F) DYKDDDDK, (Spy2) SpyTag version 2, and (H) His-6-tags.
² Fab2-FH-X22-HRP = Bivalent Fab antibody with (F) DYKDDDDK, (H) His-6-tags, and Fab-SpyTag coupled to HRP-conjugated BiCatcher.

Anti-Ixekizumab Inhibitory Antibodies (Type 1)

Type 1 anti-ixekizumab antibodies inhibit the binding of the drug ixekizumab to its target, interleukin-17A (IL-17A). They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. In fully human IgG1 format, they are suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.

Anti-Ixekizumab Non-Inhibitory Antibodies (Type 2)

The Type 2 anti-ixekizumab antibodies (TZA0106, TZA0107, and TZA0107P) bind to the ixekizumab idiotope but do not inhibit the binding of ixekizumab to IL-17A. They are ideal for development of a PK bridging ELISA to measure total ixekizumab (free and IL-17A-bound ixekizumab). The Type 2 anti-ixekizumab antibody HCA435 (AbD60554ia, human IgG1 format) is an anti-idiotypic antibody (Type 2) that specifically recognizes the free, partially bound, and fully bound humanized monoclonal antibody ixekizumab. The antibody does not inhibit the binding of ixekizumab to its target IL-17A. This antibody can be used to measure free, partially bound, and fully bound ixekizumab in serum from patients in an anti-drug antibody (ADA) assay as a surrogate positive control or calibrator.

ELISA Protocols to Get You Started

PK Bridging ELISA

Fig. 1. Ixekizumab PK bridging ELISA using antibodies TZA0105 (capture) and TZA0106P (detection).

Schematic image of PK bridging ELISA detecting free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Fab format (purple), labeled with HRP.

Fig. 2. Ixekizumab PK bridging ELISA using antibodies TZA0107 and TZA0107P.

Schematic image of PK bridging ELISA detecting total drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP. Note for ixekizumab Type 2 antibodies, the detection antibody is in Fab format.

ADA Bridging ELISA

Fig. 3. Ixekizumab ADA bridging ELISA using antibodies HCA432, HCA433, HCA434, and HCA435.

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).

Resources

Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.